This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Molecular Medicine Awards 1st Annual Ross Prize To NYU Researcher





MANHASSET, N.Y., Feb. 12, 2013 /PRNewswire-USNewswire/ -- The Feinstein Institute for Medical Research today announced that New York University ( NYU) immunology researcher Dan R. Littman, MD, PhD, will be the recipient of the first annual Ross Prize in Molecular Medicine, issued via the Feinstein Institute's peer-reviewed, open-access journal, Molecular Medicine.

(Photo: http://photos.prnewswire.com/prnh/20130212/DC58967)

Dr. Littman is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology in the Skirball Institute of Biomolecular Medicine at NYU School of Medicine.  He is a Howard Hughes Medical Institute investigator, and a member of both the National Academy of Sciences and the Institute of Medicine.

The Ross award, which includes a $50,000 prize, will be formally presented to Dr. Littman on June 24 at the New York Academy of Science in Manhattan, followed by an academic lecture by Dr. Littman and several other preeminent researchers.

The Ross Prize is awarded annually by Molecular Medicine to mid-career scientists who have made a demonstrable impact in the understanding of human diseases pathogenesis and/or treatment, and who hold significant promise for making even greater contributions to the general field of molecular medicine.

"A renowned immunologist, Dr. Littman has made seminal contributions in a number of scientific fields that advance our understanding of the immune system, HIV infections and autoimmune disease," said Feinstein Institute President Kevin J. Tracey, MD, who also serves as editor-in-chief of Molecular Medicine. "Dr. Littman and his colleagues discovered that HIV enters the body through what he terms a 'Trojan horse,' a specific type of immune cell, called an immature dendritic cell, which it then hijacks to attack other key cells of the immune system.  Dr. Littman and his team have more recently discovered a means to control inappropriate autoimmune responses to bacteria that live naturally in the human digestive system."

Dr. Littman was selected by an awards committee comprised of:

  • Christopher J. Czura, PhD, vice president, scientific affairs, and executive editor, Molecular Medicine, Feinstein Institute for Medical Research;
  • Betty Diamond, MD, head, Center for Autoimmune Diseases and Musculoskeletal Disorders, Feinstein Institute;
  • Peter K. Gregersen, MD, head, Laboratory of Genomics and Human Genetics, Feinstein Institute;
  • Göran K. Hansson, MD PhD, professor of experimental cardiovascular research, Karolinska Institute, Sweden;
  • Klas Kärre, MD PhD, professor of molecular immunology, Karolinska Institute; and
  • Kevin J. Tracey, MD, President, Feinstein Institute.

The Ross Prize was made possible by the generosity of Feinstein Institute board members Robin and Jack Ross of Upper Brookville, NY.

About Molecular Medicine

Molecular Medicine is an open access, international, peer-reviewed biomedical journal published by The Feinstein Institute for Medical Research. Molecular Medicine strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. To learn more, go to: www.molmed.org



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,851.23 -76.97 -0.43%
S&P 500 2,085.95 -3.51 -0.17%
NASDAQ 4,929.8650 -9.4620 -0.19%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs